论文部分内容阅读
据WHO报道,全球约20亿人曾感染过HBV,其中3．5亿人为慢性HBV感染者。乙型肝炎病毒感染已成为全球健康问题。我国更是HBV感染高流行区,现有1．3亿乙肝病毒携带者,3 000 多万乙型肝炎患者。目前,医务人员对慢性乙肝的诊疗水平令人担忧, 中国肝炎防治基金会于2005年公布的《中国肝炎的流行现状及其相关问题分析报告》显示,仅有19％的患者接受了抗病毒治疗。对规范化治疗意识的缺乏,给临床治疗带来严重的不良后果。有许多患者和部分医师盲目乐观,指望根治,对于无明显肝脏炎症活动的无症状HBV 携带者也给予治疗;有的过于悲观,因为害怕干扰素的严重副作用或拉米夫定停药后的病情加重而不敢用药;更有甚者,有的患者由于轻信游医或广告宣称的所谓“祖传秘方”、“基因疗法”,不仅蒙受巨大的经济损失,而且延误了病情,危害甚大。
According to the WHO, about 2 billion people worldwide have been infected with HBV, of which 350 million are chronically infected with HBV. Hepatitis B virus infection has become a global health problem. Our country is more endemic area of HBV infection, the existing 130 million hepatitis B virus carriers, more than 30 million patients with hepatitis B. At present, the medical staff’s level of diagnosis and treatment of chronic hepatitis B is worrying. The Report on the Status Quo and Related Problems of Hepatitis in China published by China Foundation for Hepatitis Prevention and Control in 2005 shows that only 19% of patients received antiretroviral therapy . The lack of awareness of standardized treatment, clinical treatment to bring serious adverse consequences. Many patients and some physicians are blindly optimistic, expect to cure, and also treat asymptomatic HBV carriers who have no obvious inflammatory activity of the liver. Some are overly pessimistic because they are afraid of the serious side effects of interferon or the condition after the withdrawal of lamivudine Worse and dare not to use medicine; what is more, some patients believe in medicine or advertising because of the so-called “secret recipe”, “gene therapy”, not only suffered huge economic losses, but also delayed the disease, endangering large.